Dapagliflozin Blocks Kidney Cell Death in Diabetes via Ketone Body Pathway
SGLT2 inhibitor dapagliflozin protects diabetic kidneys by raising β-hydroxybutyrate and suppressing iron-driven cell death (ferroptosis).
Summary
Researchers found that dapagliflozin, a widely used diabetes drug, protects kidneys in diabetic kidney disease (DKD) by inhibiting ferroptosis—a form of iron-dependent cell death driven by lipid peroxidation. Using diabetic mice and high-glucose-treated human kidney tubule cells, the team showed dapagliflozin raises levels of the ketone body β-hydroxybutyrate (BHB), which in turn suppresses a key ferroptosis regulator called CaMKK2. This restores mitochondrial function, boosts antioxidant defenses (GPX4, GSH, SLC7A11), and reduces kidney damage markers—independent of blood glucose lowering. The findings offer a mechanistic explanation for the well-documented but poorly understood renal benefits of SGLT2 inhibitors.
Detailed Summary
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease worldwide, yet effective therapies to halt its progression remain limited. SGLT2 inhibitors like dapagliflozin have demonstrated robust renal protection in large clinical trials, but the cellular mechanisms underlying this benefit—beyond glucose lowering—have been unclear. This study proposes a novel pathway: dapagliflozin protects kidney cells by suppressing ferroptosis, a regulated form of cell death characterized by iron-dependent lipid peroxidation.
The researchers used C57BL/6J mice fed a high-fat diet and treated with low-dose streptozotocin (STZ) to induce DKD, then administered dapagliflozin (5 mg/kg/day) or insulin for eight weeks. In parallel, human proximal tubule cells (HK-2) were exposed to high glucose (30 mM) with or without dapagliflozin (5 µM). Ferroptosis markers—lipid peroxidation (LPO), malondialdehyde (MDA), glutathione (GSH), GPX4, and SLC7A11—were measured alongside renal function (BUN, creatinine, 24-hour urinary protein), mitochondrial morphology via electron microscopy, mitochondrial membrane potential (MMP), ATP levels, and NAD+/NADH ratios.
DKD mice showed classic ferroptosis signatures: elevated LPO and MDA, depleted GSH and GPX4, shrunken mitochondria with lost cristae, impaired MMP, and reduced ATP. Dapagliflozin significantly reversed all of these changes—comparable to or better than insulin in several parameters—while also reducing urinary protein, BUN, creatinine, glomerular mesangial expansion, and renal fibrosis on histology. Critically, dapagliflozin markedly increased circulating and tissue levels of β-hydroxybutyrate (BHB), the primary ketone body produced during SGLT2 inhibition.
The study then focused on CaMKK2, a calcium-sensing serine/threonine kinase previously implicated in ferroptosis regulation in cancer and cardiac cells. Dapagliflozin suppressed CaMKK2 expression and phosphorylation in both kidney tissue and HK-2 cells. Pharmacological inhibition of CaMKK2 (STO609) mimicked dapagliflozin's protective effects on mitochondria and antioxidant capacity, while a CaMKK2 activator (methyl cinnamate) negated dapagliflozin's benefits—confirming CaMKK2 as a central mediator. The authors propose that BHB produced by dapagliflozin feeds into mitochondrial energy metabolism, stabilizes mitochondrial membrane potential, and downregulates CaMKK2-driven ferroptosis signaling.
These findings provide a mechanistic framework—BHB → CaMKK2 suppression → ferroptosis inhibition → renal protection—that could explain the glucose-independent nephroprotection of SGLT2 inhibitors. While promising, the study is limited by its animal and cell-culture design, small group sizes (n=6 per group), and lack of direct BHB supplementation experiments to fully confirm causality in the BHB-CaMKK2 axis.
Key Findings
- Dapagliflozin reversed ferroptosis markers (LPO, MDA, GPX4, GSH) in diabetic mice and high-glucose kidney cells.
- Dapagliflozin elevated β-hydroxybutyrate (BHB) levels, mediating its nephroprotective effects independent of glucose lowering.
- CaMKK2 expression and phosphorylation were suppressed by dapagliflozin; its inhibition mimicked renal protection.
- Mitochondrial structure, membrane potential, and ATP production were restored by dapagliflozin in DKD models.
- CaMKK2 activation abolished dapagliflozin's anti-ferroptosis and mitochondrial benefits, confirming the pathway.
Methodology
C57BL/6J mice with HFD/STZ-induced DKD received dapagliflozin or insulin for 8 weeks (n=6/group); HK-2 human proximal tubule cells were exposed to 30 mM glucose ± 5 µM dapagliflozin. Ferroptosis markers, renal function, mitochondrial morphology (TEM), MMP (flow cytometry), ATP, NAD+/NADH, BHB, and CaMKK2 signaling were assessed with pharmacological CaMKK2 inhibition/activation to confirm mechanistic pathway.
Study Limitations
The study used small animal cohorts (n=6 per group) and in vitro cell models, limiting statistical power and translational certainty. Direct proof that BHB causally drives CaMKK2 suppression (e.g., BHB supplementation rescuing DKD without dapagliflozin) was not provided. Human clinical validation of the BHB-CaMKK2-ferroptosis axis in DKD patients is still needed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.